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Ventral striatumCatecholamine depletion with alpha-methylparatyrosine (AMPT) has previously been shown to induce de-
pressive symptoms in currently remitted patients with major depressive disorder (MDD) but not healthy
controls. Thus sensitivity to catecholamine depletion has been hypothesized to be an endophenotype of
MDD. Here we tested this hypothesis in the context of a randomized, double-blinded, placebo-controlled de-
sign by measuring changes in mood in a group of psychiatrically-healthy individuals at risk of mood disorders
by virtue of family history (high-risk subjects, HRs). In addition, we tested whether HRs differed from healthy
controls with no family-history of mood disorders (low-risk controls, LRs) in their cerebral metabolic re-
sponse when undergoing catecholamine depletion. Eight healthy LRs (6 males, mean age = 34.1 ± 7.1)
and 6 healthy HRs (3 males, mean age = 29.3 ± 4.6) participated in two, 3-day-long identical sessions dur-
ing which they completed standardized measures of depression, anxiety and fatigue and an [18F]
ﬂuorodeoxyglucose (FDG) positron emission tomography (PET) scan. On one occasion participants received
4 weight-adjusted doses of AMPT and on the other occasion participants received 4 doses of placebo. The LR
and HR groups did not differ from each other in their mood during sham depletion. However, during the pe-
riod of peak catecholamine depletion, the HR group reported signiﬁcantly more depression, anxiety and fa-
tigue than the LR group. A region-of-interest analysis showed that during catecholamine depletion versus
placebo the combined LR and HR groups displayed a signiﬁcant increase in cerebral metabolic rate in the
left and right ventral striata, left and right amygdalae, and left and right hippocampi (FWE-corrected
p b 0.05). Whole brain voxel-wise analyses indicated signiﬁcantly increased glucose metabolism in the left
and right putamina (FWE-corrected p b 0.05) in the combined LR and HR groups in the AMPT versus the pla-
cebo session. In the LR group, alone, no signiﬁcant elevation in glucose metabolism was observed in the
regions-of-interest in the catecholamine depletion versus placebo condition. In the HR group, alone, the
region-of-interest analysis showed a signiﬁcant increase in cerebral metabolic rate in the left and right ven-
tral striata (FWE-corrected p b 0.05). No regions-of-interest showed signiﬁcantly different metabolism in the
HR group versus the LR group in the placebo condition, however compared with the LR group, the HR group
displayed nominally increased glucose metabolism in the left amygdala during catecholamine depletion
(SVC-corrected p = 0.05). A region-of-interest analysis for the interaction contrast conﬁrmed that catechol-
amine depletion had differential effects on HR and LR participants. Compared with the LR group, the HR
group displayed signiﬁcantly increased glucose metabolism in the left ventral striatum, left amygdala, and
left lateral orbitofrontal cortex (OFC) (FWE-corrected p b 0.05). Our results suggest that sensitivity to cate-
cholamine depletion may be a phenotypic marker of vulnerability to mood disorders that is characterizedn Research, 6655 S. Yale Ave, Tulsa, OK 74136, USA. Tel.: +1 918 502 5104.
tz).
nc. Open access under CC BY-NC-SA license.
342 J. Savitz et al. / NeuroImage: Clinical 2 (2013) 341–355at the neurophysiological level by disinhibition of the striatum and its efferent projections comprising the
limbic–cortical–striatal–pallidal–thalamic circuitry.
© 2013 The Authors. Published by Elsevier Inc.Open access under CC BY-NC-SA license.1. Introduction
We and others have previously shown that currently remitted
subjects with major depressive disorder (MDD) demonstrate signiﬁ-
cant depressive symptoms when undergoing catecholamine depletion
with alpha-methylparatyrosine (AMPT), a tyrosine hydroxylase inhibi-
tor which blocks the conversion of tyrosine to dihydroxyphenylalanine
(DOPA), the rate-limiting step in the synthesis of catecholamines
(Bremner et al., 2003; Hasler et al., 2008). The mood-lowering effect
of AMPT in remitted MDD patients is robust with average increases of
21 points on the Hamilton Depression Rating Scale (HDRS) (Berman
et al., 1999) and 10 points on the Montgomery–Asberg Depression Rat-
ing Scale (MADRS) (Hasler et al., 2008) previously reported. In contrast,
never-depressed healthy subjects without a family history of mood dis-
orders in ﬁrst-degree relatives (low-risk control subjects, LRs) are
asymptomatic or show only minor changes in mood when adminis-
tered with AMPT (Hasler et al., 2008; McCann et al., 1995; Ruhe et al.,
2007; Salomon et al., 1997). Given these data, sensitivity to catechol-
amine depletion has been proposed as an endophenotype for MDD
(Berman et al., 1999). Here we conduct the ﬁrst test of this hypothesis
by measuring changes in mood in a group of psychiatrically-healthy
individuals at risk of mood disorders by virtue of family history
(high-risk subjects, HRs) in the context of a randomized, double-blind,
placebo-controlled design.
[18F]Fluorodeoxyglucose (FDG) PET has been previously used to
evaluate the cerebral metabolic correlates of the effects of AMPT on
mood. Bremner et al. (2003) reported that MDD patients who remitted
on antidepressant treatment and subsequently relapsed after catechol-
amine depletion, showed decreased metabolism in the orbitofrontal
cortex (OFC), dorsolateral prefrontal cortex and thalamus but increased
metabolism in the middle frontal gyrus, hippocampus and amygdala in
their baseline scans (i.e. prior to receiving AMPT). More recently, we
showed that AMPT administration resulted in increased metabolism
of the striatum in both unmedicated, remitted MDD patients and
healthy controls, while during catecholamine depletion,metabolism in-
creased in the MDD subjects, but decreased in controls, in a number of
regions associated with the medial prefrontal (visceromotor) network
such as the ventromedial prefrontal cortex, thalamus, ventral striatum,
and infralimbic cortex (Hasler et al., 2008). Here we test whether HRs
differ from LRs in their cerebral metabolic response when undergoing
catecholamine depletion.
Dopamine projections from the substantia nigra and ventral teg-
mental area (VTA) to the striata, amygdalae, and prefrontal cortex
(PFC) act to inhibit neurotransmission from afferent, glutamatergic
neurons synapsing onto the striata, amygdalae, and PFC (e.g. Bunney
and Aghajanian, 1976; Goldman-Rakic et al., 1989). Similarly, norad-
renergic projections from the locus ceruleus exert a hyperpolarizing
effect on hippocampal, thalamic, and PFC neurons, inhibiting the ac-
tivity of glutamatergic neurons (Samuels and Szabadi, 2008). Because
cerebral glucose metabolism is primarily reﬂective of glutamatergic
neurotransmission (Shulman et al., 2004), we therefore hypothesized
that catecholamine depletion would disinhibit glutamatergic trans-
mission to the striatum and its efferent projections comprising the
limbic–cortical–striatal–pallidal–thalamic circuits via the depletion
of dopamine and norepinephrine. Thus due to the combined depletion
of dopamine and norepinephrine, we expected to ﬁnd increased me-
tabolism in the striatum, amygdala, hippocampus, OFC, ventromedial
PFC, and the medial thalamus. We additionally hypothesized that
this effect would be more pronounced in HR subjects than LR subjectsand that the magnitude of this response would be associated with
symptoms of depression, anxiety and fatigue.
2. Methods
2.1. Participants
Eight healthy, “low-risk” subjects with no family history of psychi-
atric illness (LRs, 6 males, mean age = 34.1 ± 7.1) and 6 healthy
“high-risk” subjects with at least one ﬁrst-degree relative and/or mul-
tiple second relatives with either bipolar disorder or recurrent MDD
(HRs, 3 males, mean age = 29.3 ± 4.6) participated in the study
after giving informed consent as approved by the NIMH IRB. Two HR
subjects had a family history of bipolar disorder and 4 subjects had a
family history of MDD (see Supplementary data ﬁle for more detailed
information). Diagnosis was established using the Structured Clinical
Interview for the DSM-IV (SCID-IV) (First et al., 1995) and conﬁrmed
by an unstructured interview with a psychiatrist. Family history was
established using the Family Interview for Genetic Studies (FIGS)
(Maxwell, 1992). Subjects were recruited through advertisements in
local newspapers and posters placed at the NIH campus, local colleges,
ﬁtness centers, and libraries.
The following exclusion criteria applied: inability to provide in-
formed consent, current pregnancy (as documented by pregnancy
testing at screening or at days of the challenge studies), age b18 and
>45, personal history of psychiatric illness (or family history of psy-
chiatric illness in the case of the LRs), cigarette smoking, use of alcohol
(>4 oz/day for men and >3 oz/day for women), lactose intolerance,
signiﬁcant medical or neurological disorders likely to affect physiolo-
gy or anatomy, (e.g. hypertension, cardiovascular disorders, and dia-
betes), past head injury with loss of consciousness, general MRI and
PET exclusion criteria (e.g. metallic implants, exposure to more than
5 rem of radiation within the past year), abnormalities on the
Chem-20, including electrolyte disturbance and anemia, or positive
drug, hepatitis or HIV screen.
2.2. Experimental design
In a randomized, double-blind, placebo-controlled design, subjects
participated in two identical sessions separated by at least one week
(in order to avoid carry-over effects) in which they received either
AMPT or placebo. Subjects were admitted to the inpatient unit at the
NIH Clinical Center for 3 days per session (6 in total) where they re-
ceived psychological assessments and underwent a PET scan and
blood draws to measure serum prolactin levels (Fig. 1). Serum prolac-
tin levels (μg/L), which were obtained to conﬁrm catecholamine
depletion, were measured using an electrochemiluminescent immu-
noassay (Boehringer, Mannheim, Germany). The PET images were
obtained ~27 h after the ﬁrst dose of AMPT or placebo corresponding
to the time of maximum catecholamine depletion reported in previ-
ous studies (Berman et al., 1999; Bremner et al., 1997). Patients
were placed on a low-monoamine diet for the duration of their stay
in the inpatient unit in order to minimize dietary effects on mono-
amine levels.
In order to mitigate the risk of adverse reactions such as akathisia,
dystonia or postural hypotension, a weight-adjusted AMPT dose of
40 mg/kg up to a maximum of 4 g was administered orally over a
24-hour period (Hasler et al., 2008) (Fig. 1). Adverse effects were
reported in some studies in response to doses of AMPT >4 g (de
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Fig. 1. Flow-chart showing the experimental procedure for a study session. Each participant completed 2 identical sessions, on one occasion receiving AMPT, and on the other occasion
receiving placebo. Each participant was given 3 weight-adjusted doses of AMPT/placebo on day 1, and one dose of AMPT/placebo on day 2 so that the period of maximum depletion
coincided approximately with the PET scanning session on day 2. Each participant also completed four clinical/behavioral interviews to capture changes in mood and fatigue over the
course of the catecholamine depletion procedure. The blue bars represent the blood draws. The green bars represent the times of AMPT or placebo administration. The orange bars
show the times at which sodium bicarbonate was administered to the subjects (to prevent crystalluria). The purple blocks represent the behavioral/clinical assessment sessions, and
the mottled blue block represents the PET scanning session.
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participants. Tominimize the risk of crystaluria during AMPT adminis-
tration, subjects received 650 mg sodium bicarbonate on evenings
one and two (Fig. 1), and drank at least 2 L of water daily. In addition,
urine analysis was performed twice daily to screen for the presence of
crystals.
2.3. Clinical ratings
Both clinician-administered and self-rating scales were administered
to the participants. The 24-item version of the Hamilton Rating Scale for
Depression (HDRS) (Hamilton, 1960) and theMADRS (Montgomery and
Asberg, 1979) were administered by raters (research nurses, 2 physi-
cians, and a clinical psychologist), who trained together to establish
interrater reliability with an intra-class correlation coefﬁcient of ~0.8.
Self-rating scales, whichwere used to evaluate changes inmood, anxiety,
and drowsiness, consisted of the Beck Depression Inventory (BDI) (Beck
and Steer, 1993), Spielberger State-Trait Anxiety Inventory (STAI)
(Spielberger et al., 1970), the Proﬁle of Mood States (POMS) (Pollock et
al., 1979), the Visual Analog Scales (VAS) (Stern, 1997), and the Stanford
Sleepiness Scale (SSS) (Hoddes et al., 1972).
2.4. Clinical data analysis
Differences in behavioral ratings between the groups and across the
placebo and AMPT sessions were assessed using repeated measures
ANOVA. We were primarily interested in the interaction between
group (HR versus LR), session (AMPT versus placebo) and time (0 h,
24 h, 30 h, and 48 h post initial dose of drug/placebo). In the case of a
signiﬁcant interaction, post-hoc t-tests were used to perform speciﬁc
contrasts. In order to conﬁrm the results of the repeated measures
ANOVA, we also analyzed the data with the nonparametric Mann–
Whitney test with a X2 approximation. Because we hypothesized apriori that AMPT would induce greater mood symptoms in the HR
group, and that the behavioral ratings obtained 24 h and 30 h post ini-
tial dose of AMPT would be most sensitive to catecholamine depletion,
all p-values obtained from t-tests and X2 tests are one-tailed, with the
signiﬁcance threshold set at p b 0.05.
Correlations between normalized glucose metabolism at the peak
voxel coordinates representing the left and right striata and the clin-
ical measures described above were measured using the nonparamet-
ric Spearman's Rho test. All correlation analyses were conducted on
the data derived from the catecholamine depletion condition only.
2.5. Imaging
Regional cerebral glucose metabolism was measured with a High-
Resolution-Research Tomograph PET scanner (HRRT, Siemens ECAT:
207, 1.22 mm slices, 3D resolution ~2.5 mm3). Ten mCi of 18FDG was
administered by i.v. slow bolus injection (over 2 min) using a Harvard
pump. In order to quantitatively model the cerebral glucose utilization
non-invasively, an initial emission scan was acquired over the heart
on a whole body GE Advance Scanner (GEMedical Systems, Waukesha,
WI) during the initial 35 min period following 18FDG administration
(Moore et al., 2003). In addition, a transmission scan with 68Ge was ac-
quired on the GE Advance Scanner for attenuation correction of the car-
diac emission scan during the tracer uptake period.
After completion of the cardiac emission scan the participant was
subsequently moved to the HRRT scanner. Using the HRRT, a 20 min
emission scan was acquired over the brain as subjects rested with
eyes-closed, beginning 45 min after the 18FDG administration. Follow-
ing the emission scan, a transmission scan of the head was obtained
using 137Cs for attenuation correction of the cerebral emission scan.
Whole brain structural MRI scans with a spatial resolution of
~1 mm3 were acquired separately using a 3 T scanner (Signa, GE
Medical Systems) and T1-weighted magnetization prepared rapidly
344 J. Savitz et al. / NeuroImage: Clinical 2 (2013) 341–355acquired gradient echo (MPRAGE) pulse sequence in order to facili-
tate localization and co-registration of the functional PET data.
2.6. Imaging data analysis
We were primarily interested in answering 2 questions. Firstly, how
does regional cerebral glucose metabolism differ between drug and pla-
cebo sessions across all subjects, and secondly, does catecholamine deple-
tion have a differential impact on regional cerebral glucosemetabolism in
the LR and HR groups? We tested these hypotheses with repeated mea-
sures ANOVA using Statistical Parametric Mapping software (SPM5;
Wellcome Department of Imaging Neuroscience, London, England). The
PET images were co-registered with the MRI images and spatially nor-
malized to the Montreal Neurological Institute (MNI) T1 template. Im-
ages were smoothed using a 10 mm Gaussian kernel to compensate for
individual differences in neuroanatomy and misalignment errors in spa-
tial normalization. Note that one LR individual was omitted from the
PET analysis due to a normalization failure.
Regional metabolism was compared across groups and conditions in
predeﬁned regions-of-interest in the ventral striatum, amygdala, hippo-
campus,mediodorsal thalamus, OFC, ventromedial prefrontal cortex, and
subgenual anterior cingulate cortex (sgACC). The ROIs were selected on
the basis of our previous report of changes in regional cerebral glucose
metabolism during catecholamine depletion (Hasler et al., 2008) as
well as the model of Drevets et al. (1992), which in turn was based on
the study of Swerdlow and Koob that discussed the effects of dopamine
depletion on limbic–cortical–striatal–pallidal–thalamic neurocircuitry
(Swerdlow and Koob, 1987). A sphere of 8 mm radius (4 mm in the
case of the relatively smaller amygdala) was deﬁned around the spatial
coordinate that best represented the stereotaxic center of each ROI
(these coordinate sets are listed in the legend for Table 2). The spatial
coordinates were selected on the basis of the neuroanatomical atlases
of Mai et al. (2004) and Talairach and Tournoux (1988) except in the
case of the ventral striatum where we followed the methodology of
Nusslock et al. (2012) and the ventromedial frontal polar cortex where
we used the locus where Hasler et al. (2008) found a signiﬁcant positive
correlation between the change in metabolism and the severity of de-
pression under AMPT challenge in their sample (Tables 2 and 3). Using
the small volume correction (SVC) option within SPM5, each ROI was
searched for voxel t-values corresponding to pcorrected b 0.05 using the
family-wise error (FWE) correction for multiple testing. A cluster of at
least 10 contiguous voxels that yielded a corrected p-value b 0.05 was
considered to be statistically signiﬁcant.
Whole brain voxel-wise analyses were conducted post-hoc in order
to explore whether metabolic changes occurred in other brain regions.
To assess the presence of other metabolic differences the signiﬁcance
threshold was set at a corrected p-value b 0.05 after applying the false
discovery rate (FDR) error correction across the entire brain. In addition,
this image was evaluated to ensure that the peak voxel t-values identi-
ﬁed in the ROI analyses actually were encompassed within the target
ROI (albeit at lower signiﬁcance thresholds).
We were unable to accurately calculate the input function neces-
sary to model regional cerebral glucose utilization for 6 of the 28
scans because clotting in the intravenous line prohibited some blood
draws needed to complete the input function. Consequently, all the
data were analyzed using the tissue radioactivity concentrations,
which were globally normalized by the whole brain 18FDG uptake.
3. Results
3.1. Prolactin measurements
Both LR and HC groups showed a signiﬁcant increase in prolactin
levels indicative of catecholamine depletion 24–48 h after administra-
tion of the ﬁrst dose of AMPT (Fig. 2, F = 25.2, p b 0.001). Neither the
basal prolactin levels nor the change in prolactin levels under AMPTdiffered between the groups during either the placebo or AMPT ses-
sions (F = 0.832, p = 0.371). Fig. 2 indicates the time points at
which prolactin levels are signiﬁcantly elevated in the AMPT session
relative to the placebo session.
3.2. AMPT-associated changes in mood
Relative to the LR group, the HR group showed signiﬁcant eleva-
tions in self-reported depression, anxiety and fatigue 24 h (time 2)
and 30 h (time 3) after the ﬁrst dose of AMPT (Tables 1 and 2,
Figs. 3–11). With the exception of the MADRS (Fig. 7), the LR and HR
groups did not differ from each other during sham depletion. The
red stars on the ﬁgures indicate a statistically signiﬁcant difference be-
tween the LR and HR groups for the relevant time point according to
the Mann–Whitney test.
3.3. FDG PET data analyses
3.3.1. Region of interest analyses
3.3.1.1. Effect of AMPT versus placebo in the combined sample. Consis-
tent with our hypothesis, the combined HR and LR samples showed
signiﬁcant (FWE-corrected) increases in normalized glucose utiliza-
tion in the right ventral striatum, the left and right amygdalae, and
the left and right hippocampi (Table 3, Fig. 12).
3.3.1.2. Differential effects of AMPT versus placebo across groups. In the
placebo condition, no signiﬁcant difference in the normalized
(regional-to-global) metabolism was observed in the LR group com-
pared with the HR group. Compared with the LR participants, the
HR participants displayed a nominally signiﬁcant elevation in
regional-to-global metabolism in the left amygdala (Table 4) during
catecholamine depletion.
In the LRgroup, alone, no signiﬁcant elevation in glucosemetabolism
was observed in the catecholamine depletion versus placebo condition.
In the HR group, alone, therewas a signiﬁcant increase inmetabolism in
the left and right ventral striata (FWE-corrected p b 0.05) in the cate-
cholamine depletion versus placebo condition (Table 5).
Compared with the LR participants, the HR participants displayed
signiﬁcantly elevated regional-to-global metabolism in the left stria-
tum, left amygdala, and left OFC in the catecholamine depletion versus
placebo condition (interaction contrast, Table 6, Fig. 12).
3.3.2. Post-hoc whole brain voxel-wise analyses
3.3.2.1. Effect of AMPT versus placebo in the combined HR and LR sam-
ples. During catecholamine depletion, a signiﬁcant increase in metabo-
lism was found in the bilateral ventral striatum, with the peak voxel
t-value localizing speciﬁcally to the left anteroventral putamen (cluster
size = 137, FWE-corrected p = 0.028) and the right anteroventral pu-
tamen (cluster size = 328, FWE corrected p = 0.038, Table 7, Fig. 13).
No brain regions showed a signiﬁcant decrease in metabolism in the
AMPT versus the placebo contrast after applying the conservative
FWE correction for multiple comparisons across the whole brain.
3.3.2.2. Differential effects of AMPT versus placebo across groups. In the
LR group, alone, no signiﬁcant difference in glucose metabolism was
observed in the catecholamine depletion versus placebo condition
after applying the FWE-correction formultiple comparisons. Similarly,
in the HR group, alone, no signiﬁcant difference in glucosemetabolism
was observed in the catecholamine depletion versus placebo condi-
tion. No brain regions showed a signiﬁcant difference between the
HR and LR groups after applying the FWE-correction formultiple com-
parisons in either the placebo condition or the AMPT condition. No
brain region showed a signiﬁcantly different AMPT-induced change
Placebo
T0 T0T24 T24T30 T30T48 T48
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Fig. 2. This ﬁgure shows the mean plasma prolactin levels in both the LR and HR groups across the placebo (ﬁgure to the left) and AMPT sessions (ﬁgure to the right) for all 4 session
time points. That is, T0, T24, T30, and T48 where T0 represents the baseline measure prior to administration of AMPT/placebo (blue color), T24 represents the prolactin levels of
24 h post administration of AMPT/placebo (green color), T30 represents the prolactin levels of 30 h post administration of AMPT/placebo (gold color), and T48 represents the pro-
lactin levels of 48 h post administration of AMPT/placebo (purple color). The error bars represent the standard error of the mean. The red stars show the time points at which the
prolactin levels in each subject group differed (Mann–Whitney test, p b 0.05) between the placebo and AMPT conditions. Dopamine neurons project from the arcuate nucleus of the
hypothalamus to the pituitary gland where they exert an inhibitory effect on prolactin secretion. Thus an increase in prolactin levels is expected during catecholamine depletion.
345J. Savitz et al. / NeuroImage: Clinical 2 (2013) 341–355in metabolism between groups after applying the FWE correction for
multiple comparisons (interaction contrast).
3.4. Correlations between striatal cerebral glucose metabolism and be-
havioral ratings
Within the combined LR and HR groups there were no signiﬁcant
correlations between the normalized cerebral glucose metabolism
under catecholamine depletion in the left and right ventral striata and
the clinical measures of mood, anxiety and fatigue (Table 8). In the HR
group, alone, however, the normalized metabolism of the right striatumTable 1




Scale N T0 T24 T30 T
Prolactin (μg/L) 8 9.4 ± 4.7 12.0 ± 9.6 7.4 ± 3.0 1
6 7.8 ± 2.4 11.2 ± 5.8 10.4 ± 5.1 1
BDI 5 0.5 ± 1.0 0.5 ± 1.0 0 ± 0
5 1.0 ± 1.3 0.5 ± 0.8 0.7 ± 1.0
POMS depression 7 0.3 ± 0.8 0.4 ± 1.1 0.6 ± 1.1
6 0.7 ± 1.6 0.2 ± 0.4 0.2 ± 0.4
VAS sadness 7 0.5 ± 0.8 0.1 ± 0.2 0.1 ± 0.4
6 0.3 ± 0.8 0.3 ± 0.8 0.3 ± 0.8
HAM-D 8 0.1 ± 0.4 0.1 ± 0.4 0.1 ± 0.4
6 1 ± 1.3 1.2 ± 1.8 1.3 ± 2.0
MADRS 8 0.3 ± 0.7 0.1 ± 0.4 0 ± 0
6 2.2 ± 2.6 1.8 ± 1.2 1.2 ± 0.4
STAI (State) 7 22.6 ± 3.4 25.0 ± 5.3 24.3 ± 5.4 2
6 24.5 ± 5.0 25.3 ± 7.5 24.2 ± 6.9 2
POMS tension 7 0.7 ± 1.5 1.1 ± 1.9 0.6 ± 1.1
6 1.3 ± 1.0 0.3 ± 0.8 0.3 ± 0.8
POMS fatigue 7 1.5 ± 2.4 1.6 ± 2.4 1.3 ± 2.4
6 2.7 ± 4.7 1.7 ± 2.7 0.5 ± 0.5
Sleepiness (SSS) 7 1.7 ± 0.8 1.7 ± 1.0 1.3 ± 0.5
6 1.7 ± 0.8 1.7 ± 0.8 1.3 ± 0.5
Note: The sample size varied slightly across questionnaires because not all subjects complet
30 h, and 48 h post ﬁrst dose of AMPT/placebo, respectively.
Abbreviations: BDI = Beck Depression Inventory; POMS = Proﬁle of Mood States; VAS = Vis
Asberg Depression Rating Scale; STAI (State) = The state subscale of the State-Trait Anxiety Scorrelated positively with scores on the POMS tension factor (r = 0.98,
p = 0.002), the POMS fatigue factor (r = 1, p b 0.001), and theStanford
Sleepiness Scale scores (r = 0.82, p = 0.044).
4. Discussion
The previously observed depressive and anhedonic responses pre-
cipitated by catecholamine depletion in remitted patients with MDD
have raised the possibility that dysfunction of the dopaminergic/norad-
renergic system constitutes a potentially latent characteristic of MDD.




48 T0 T24 T30 T48
0.3 ± 6.6 8.9 ± 2.6 18.7 ± 5.4 22.3 ± 10.9 15.8 ± 6.5
0.5 ± 5.4 7.2 ± 1.7 24.7 ± 6.2 31.3 ± 9.5 13.4 ± 4.8
0.2 ± 0.4 0 ± 0 0 ± 0 0 ± 0 0 ± 0
0.3 ± 0.8 1.2 ± 1.9 10.8 ± 9.4 7.1 ± 9.5 1.8 ± 4.5
0.4 ± 1.1 0 ± 0 0.4 ± 0.9 0 ± 0 0 ± 0
0.3 ± 0.8 1.6 ± 1.8 5.6 ± 6.3 4.6 ± 6.6 0.6 ± 1.3
0.3 ± 0.5 0.1 ± 0.2 0.1 ± 0.2 0.1 ± 0.2 0.1 ± 0.3
0.3 ± 0.8 0.5 ± 0.6 2.4 ± 2.3 2.0 ± 1.4 1.0 ± 1.2
0 ± 0 0 ± 0 3.5 ± 4.7 1.3 ± 2.2 1.5 ± 3.7
0.3 ± 0.8 0.2 ± 0.4 7.2 ± 5.4 4.8 ± 4.9 1.8 ± 4.0
0.1 ± 0.3 0 ± 0 4.8 ± 7.1 1.7 ± 3.2 1.7 ± 4.1
0.3 ± 0.5 1.2 ± 1.5 8.8 ± 8.3 7.8 ± 8.4 2.8 ± 5.1
4.4 ± 4.4 23.0 ± 5.7 24.4 ± 7.1 23.0 ± 6.2 23.3 ± 4.0
4.3 ± 7.3 27.4 ± 8.4 42.6 ± 12.0 36.8 ± 8.2 26.0 ± 7.4
0.7 ± 1.5 0 ± 0 0.8 ± 1.3 0.2 ± 0.4 0 ± 0
1.0 ± 1.3 3.6 ± 3.0 8.8 ± 7.5 5.2 ± 6.7 0.4 ± 0.5
1.1 ± 0.4 3.4 ± 5.5 3.0 ± 3.7 1.0 ± 1.7 0.3 ± 0.5
1.2 ± 1.8 1.4 ± 0.9 14.2 ± 2.0 10.6 ± 7.7 1.8 ± 1.8
1.4 ± 0.5 2.0 ± 1.0 2.6 ± 0.5 1.8 ± 0.4 1.0 ± 0
1.5 ± 0.5 1.5 ± 1.0 5.2 ± 1.9 3.6 ± 1.1 1.4 ± 0.5
ed the full battery of scales across all 8 time points. T0, T24, T30, and T48 = 0 h, 24 h,
ual Analog Scale; HAM-D = Hamilton Depression Rating Scale; MADRS = Montgomery–
cale; Sleepiness (SSS) = Stanford Sleepiness Scale.
Table 2
Statistical analysis of AMPT-associated changes in mood, anxiety, and fatigue in low-risk versus high-risk participants.
Scale Repeated measures ANOVA
DX ∗ session ∗ time
Post-hoc t-test
(signiﬁcant results)
Mann–Whitney with Χ2 approximation
(signiﬁcant results)
Interpretation
BDI F = 2.4, p = 0.015 During AMPT session, HR > LR at times:
P = 0.029 Χ2 = 4.4, p = 0.036 2
– Χ2 = 4.2, p = 0.040 3
POMS depression F = 2.8, p = 0.050 During AMPT, HR > LR at times:
P = 0.042 – 1
P = 0.054 Χ2 = 4.1, p = 0.044 2
– Χ2 = 3.7, p = 0.054 3
VAS sadness F = 2.2, p = 0.010 During AMPT, HR > LR at times:
P = 0.029 Χ2 = 4.5, p = 0.034 2
P = 0.009 Χ2 = 4.6, p = 0.032 3
HAM-D F = 1.2 p = 0.322 During AMPT, a trend for HR > LR at time 3
– Χ2 = 2.8, p = 0.097
MADRS F = 1.0, p = 0.394 During AMPT, HR > LR at times:
– Χ2 = 3.6, p = 0.058 1
– Χ2 = 3.8, p = 0.050 3
During placebo, HR > LR at times:
– Χ2 = 4.1, p = 0.042 1
– Χ2 = 9.9, p = 0.002 2
Χ2 = 6.7, p = 0.010 3
STAI (State) F = 3.7, p = 0.016 During AMPT, HR > LR at times:
P = 0.010 Χ2 = 4.9, p = 0.029 2
P = 0.009 Χ2 = 4.5, p = 0.034 3
POMS tension F = 3.0, p = 0.039 During AMPT, HR > LR at times:
P = 0.015 Χ2 = 5.5, p = 0.019 1
P = 0.023 Χ2 = 7.0, p = 0.008 2
POMS fatigue F = 8.9, p b 0.001 During AMPT, HR > LR at times:
P b 0.001 Χ2 = 7.0, p = 0.008 2
P = 0.013 Χ2 = 5.9, p = 0.015 3
Sleepiness (SSS) F = 5.6, p = 0.002 During AMPT, HR > LR at times:
P = 0.010 Χ2 = 5.7, p = 0.017 2
P = 0.006 Χ2 = 5.5, p = 0.019 3
Note: p-values are from one-tailed statistical tests. DX = diagnosis; Session = AMPT/Placebo; Time = time points within a session — 0 h, 24 h, 30 h, and 48 h post ﬁrst dose of
AMPT/placebo, where 0 = 1, 24 = 2, 30 = 3, and 48 = 4.
Abbreviations: BDI = Beck Depression Inventory; POMS = Proﬁle of Mood States; VAS = Visual Analog Scale; HAM-D = Hamilton Depression Rating Scale; MADRS = Montgomery–
Asberg Depression Rating Scale; STAI (State) = The state subscale of the State-Trait Anxiety Scale; Sleepiness (SSS) = Stanford Sleepiness Scale.
346 J. Savitz et al. / NeuroImage: Clinical 2 (2013) 341–355catecholamine function by administration of AMPT would induce de-
pressive symptoms alongwith changes in regional cerebral glucoseme-
tabolism in a subset of unaffected relatives who are at genetic risk for
developing a mood disorder by virtue of their family history.
As hypothesized, compared with LR participants, HR participants
showed signiﬁcant increases in symptoms of depression, anxiety andPlacebo
T0 T0T24 T24T30 T30T48 T48
Fig. 3. This ﬁgure shows the change in Beck Depression Inventory scores in both the LR and H
for all 4 session time points. That is, T0, T24, T30, and T48 where T0 represents the baseline sc
of 24 h post administration of AMPT/placebo (green color), T30 represents the BDI scores
scores of 48 h post administration of AMPT/placebo (purple color). The error bars represe
T30 differed signiﬁcantly between the placebo and AMPT sessions in the HR but not the LRfatigue during catecholamine depletion. Because activation of the
locus ceruleus is closely correlated with level of arousal and wakeful-
ness (Samuels and Szabadi, 2008), the increased levels of fatigue and
sleepiness observed in theHR group during the AMPT condition suggest
that people with a genetic predisposition to mood disorders may con-
ceivably be more sensitive to perturbations in the level of intrasynapticT0
AMPT
T0T24 T24T30 T30T48 T48
R groups across the placebo (ﬁgure to the left) and AMPT sessions (ﬁgure to the right)
ore prior to administration of AMPT/placebo (blue color), T24 represents the BDI scores
of 30 h post administration of AMPT/placebo (gold color), and T48 represents the BDI
nt the standard error of the mean. The red stars show that the BDI scores at T24 and
group (Mann–Whitney test, p b 0.05).
Placebo
T0 T0 T0T24 T24T30 T30T48 T48
AMPT
T0T24 T24T30 T30T48 T48
Fig. 4. This ﬁgure shows the change in the Proﬁle of Mood States (POMS) depression scale scores in both the LR and HR groups across the placebo (ﬁgure to the left) and AMPT sessions
(ﬁgure to the right) for all 4 session time points. That is, T0, T24, T30, and T48where T0 represents the baseline score prior to administration of AMPT/placebo (blue color), T24 represents
the POMS depression scores of 24 h post administration of AMPT/placebo (green color), T30 represents the POMS depression scores of 30 h post administration of AMPT/placebo (gold
color), and T48 represents the POMS depression scores of 48 h post administration of AMPT/placebo (purple color). The error bars represent the standard error of themean. The red stars
show that the POMS depression scores at T24 and T30 differed signiﬁcantly between the placebo and AMPT sessions in the HR but not the LR group (Mann–Whitney test, p b 0.05).
347J. Savitz et al. / NeuroImage: Clinical 2 (2013) 341–355and/or extrasynaptic norepinephrine. Potentially consistent with this
hypothesis, norepinephrine reuptake inhibitors such as reboxetine are
sometimes used as antidepressant medications and may also be used
to treat depression with high levels of fatigue (Bould et al., 2012). The
AMPT-associated increase in fatigue, anxiety, and depression is also po-
tentially consistent with reports of decreased expression of norepi-
nephrine transporters in the locus ceruleus of patients with a history
of depression (Klimek et al., 1997). The data are also potentially consis-
tent with increased levels of tyrosine hydroxylase in the locus ceruleus
of suicide cases (Ordway et al., 1994; Zhu et al., 1999), increased mRNA
expression of α2-adrenoceptors in the frontal cortex of patients who
had committed suicide (Valdizan et al., 2010), and increased binding
of an α2-adrenoceptor agonist in the locus ceruleus of patients with a
history of depression at postmortem (Ordway et al., 2003). Conceivably,
the decreased expression of norepinephrine transporters together withPlacebo
T0 T0T24 T24T30 T30T48 T48
Fig. 5. This ﬁgure shows the change in the Visual Analog Scale (VAS) sadness scores in both t
the right) for all 4 session time points. That is, T0, T24, T30, and T48 where T0 represents the
VAS sadness scores of 24 h post administration of AMPT/placebo (green color), T30 represen
T48 represents the VAS sadness scores of 48 h post administration of AMPT/placebo (purple
the VAS scores at T24 and T30 differed signiﬁcantly between the placebo and AMPT sessionthe increased expression of α2-adrenoceptors reﬂects a compensatory
response to decreased levels of norepinephrine. In support of this hy-
pothesis, depletion of norepinephrine has been shown to upregulate
α2-adrenoceptors in rodents.
Changes in the expression and/or sensitivity of dopamine receptors
have also been found in patients with a history of depression at post-
mortem (Savitz and Drevets, 2012). For example, the percentage of
D1-expressing neurons as well as D1 mRNA expression was increased
by 25% in the CA3 region of the hippocampus in patients with BD
(Pantazopoulos et al., 2004) and increased D2 receptor binding was
found in the amygdalae of depressed patients (Klimek et al., 2002). In
addition, two PET studies have reported a reduction in the binding po-
tential of the dopamine transporter in MDD (Meyer et al., 2001) and
BD (Anand et al., 2011), respectively. We previously hypothesized
that one interpretation of the decrease in dopamine transporter bindingAMPT
T0 T0T24 T24T30 T30T48 T48
he LR and HR groups across the placebo (ﬁgure to the left) and AMPT sessions (ﬁgure to
baseline score prior to administration of AMPT/placebo (blue color), T24 represents the
ts the VAS sadness scores of 30 h post administration of AMPT/placebo (gold color), and
color). The error bars represent the standard error of the mean. The red stars show that
s in the HR but not the LR group (Mann–Whitney test, p b 0.05).
Placebo
T0 T24 T30 T48 T0 T24 T30 T48
AMPT
T0 T24 T30 T48 T0 T24 T30 T48
Fig. 6. This ﬁgure shows the change in theHamiltonDepression scale (HAM-D) scores in both the LR andHRgroups across the placebo (ﬁgure to the left) and AMPT sessions (ﬁgure to the
right) for all 4 session time points. That is, T0, T24, T30, and T48 where T0 represents the baseline score prior to administration of AMPT/placebo (blue color), T24 represents the HAM-D
scores of 24 h post administration of AMPT/placebo (green color), T30 represents the HAM-D scores of 30 h post administration of AMPT/placebo (gold color), and T48 represents the
HAM-D scores of 48 h post administration of AMPT/placebo (purple color). The error bars represent the standard error of the mean. The red star indicates that the HAM-D scores at
T30 differed signiﬁcantly between the placebo and AMPT sessions in the HR but not the LR group (Mann–Whitney test, p b 0.05).
348 J. Savitz et al. / NeuroImage: Clinical 2 (2013) 341–355potential is that it reﬂects a compensatory response to decreased dopa-
minergic signaling in the ventral striatum (Savitz and Drevets, 2012). In
support of this hypothesis, dopamine transporter density decreases
after chronic dopamine depletion (Gordon et al., 1996), suggesting
that at least some types of depression may be associated with low
basal levels of intrasynaptic dopamine (Savitz and Drevets, 2012). Con-
sistent with these data, both currently depressed and remitted MDD
subjects have markedly decreased levels of the dopamine catabolite,
homovanillic acid (HVA) in the cerebrospinal ﬂuid (Asberg et al.,
1984; Kaddurah-Daouk, 2012). Our results raise the possibility that
some HR subjects also have low basal levels of intrasynaptic dopamine
and norepinephrine rendering them sensitive to themood-lowering ef-
fects of AMPT, which putatively induces reductions in plasma MHPG
and HVA in healthy controls (Salomon et al., 1997), patients with
MDD (Berman et al., 1999; Miller et al., 1996), and patients withT0 T24 T24T0T30 T30T48 T48
Placebo
Fig. 7. This ﬁgure shows the change in the Montgomery–Asberg Depression Rating Scale (M
AMPT sessions (ﬁgure to the right) for all 4 session time points. That is, T0, T24, T30, and T48
color), T24 represents the MADRS scores of 24 h post administration of AMPT/placebo (gree
(gold color), and T48 represents the MADRS scores of 48 h post administration of AMPT/pl
stars indicate that during the placebo condition, the HR group had signiﬁcantly higher MADR
higher MADRS scores than the LR group at T30. Two red stars: p b 0.01, one red star p b 0.seasonal affective disorder (Lam et al., 2001). However, because we
did not obtain measures of central dopamine or norepinephrine func-
tion, our study design does not allow us to deﬁnitely address this
hypothesis.
Consistent with a previous study (Hasler et al., 2008) there was no
main effect of diagnosis (HR versus LR) and no diagnosis by treatment
interaction on serum prolactin levels, an arguably counterintuitive
ﬁnding if a depressive diathesis is indeed associated with lower
basal levels of dopamine. One possibility is that the putative reduction
in dopaminergic signaling is speciﬁc to particular dopaminergic path-
ways (e.g. the mesolimbic dopaminergic pathway); i.e. MDD and HR
subjects may not differ from LR subjects in terms of dopaminergic sig-
naling within the tuberoinfundibular dopaminergic pathway. There is
a precedent for pathway-speciﬁc abnormalities in dopamine function
in the psychiatric literature. Schizophrenia has been hypothesized toT0 T24 T24T0T30 T30T48 T48
AMPT
ADRS) scores in both the LR and HR groups across the placebo (ﬁgure to the left) and
where T0 represents the baseline score prior to administration of AMPT/placebo (blue
n color), T30 represents the MADRS scores of 30 h post administration of AMPT/placebo
acebo (purple color). The error bars represent the standard error of the mean. The red
S scores than the LR group at T0, T24, and T30. In the AMPT condition, the HR group had
05. Refer to Table 2 for more detail.
Placebo
T0 T0T24 T24T30 T30T48 T48
AMPT
T0 T0T24 T24T30 T30T48 T48
Fig. 8. This ﬁgure shows the change in the State subscale of the State-Trait Anxiety Inventory (STAI) scores in both the LR and HR groups across the placebo (ﬁgure to the left) and
AMPT sessions (ﬁgure to the right) for all 4 session time points. That is, T0, T24, T30, and T48 where T0 represents the baseline score prior to administration of AMPT/placebo (blue
color), T24 represents the STAI scores of 24 h post administration of AMPT/placebo (green color), T30 represents the STAI scores of 30 h post administration of AMPT/placebo (gold
color), and T48 represents the STAI scores of 48 h post administration of AMPT/placebo (purple color). The error bars represent the standard error of the mean. The red stars show
that the VAS scores at T24 and T30 differed signiﬁcantly between the placebo and AMPT sessions in the HR but not the LR group (Mann–Whitney test, p b 0.05).
349J. Savitz et al. / NeuroImage: Clinical 2 (2013) 341–355be characterized by a hyperactive mesolimbic dopaminergic pathway,
resulting in stimulation of D2 receptors and positive disease symp-
toms, but a hypoactive mesocortical dopaminergic pathway, resulting
in negative disease symptoms (Abi-Dargham and Moore, 2003;
Weinberger, 1987).
We hypothesized above that catecholamine depletion would dis-
inhibit the limbic–cortical–striatal neural circuits previously implicat-
ed in depression (Savitz and Drevets, 2009a, 2009b) resulting in an
increase in cerebral metabolic rate in these structures. Shulman et
al. (2004) reviewed the magnetic resonance spectroscopy literature
and showed that the activity of glutamatergic neurons consumes
about 85% of the total energy consumed by the brain. Because dopa-
mine projections from the substantia nigra and ventral tegmental
area synapse onto afferent glutamatergic projections of the striatum,
amygdala, and PFC and inhibit neuronal activity, depletion of dopa-
mine would be expected to disinhibit the efferent projections of thePlacebo
T0 T0T24 T24T30 T30T48 T48
Fig. 9. This ﬁgure shows the change in the POMS tension scores in both the LR andHR groups ac
time points. That is, T0, T24, T30, and T48where T0 represents the baseline score prior to admini
administration of AMPT/placebo (green color), T30 represents the POMS tension scores of 30 h
scores of 48 h post administration of AMPT/placebo (purple color). The error bars represent th
T30 differed signiﬁcantly between the placebo and AMPT sessions in the HR but not the LR grostriatum, amygdala, and PFC; an effect that has previously been dem-
onstrated (Bunney and Aghajanian, 1976; Goldman-Rakic et al., 1989;
Kerkerian et al., 1987; Wooten and Collins, 1981). Nevertheless, we
note that the signal derived from 18F-FDGmay also be reﬂective of ac-
tivity in other neuronal circuits and should not be regarded as mech-
anistically selective.
Given the extensive interaction between the dopaminergic, norad-
renergic and serotonergic systems, the increase in anxiety and depres-
sive symptoms in the HR group with AMPT depletion is potentially
consistentwith a number of studies that assessed the effect of serotonin
depletion onmood in healthy individuals with a family history of mood
disorders (deﬁned as at least one-ﬁrst degree relative with depression).
In one study, 6 out of 20 healthy males have a family-history of MDD or
bipolar disorder but 0 out of 19 male controls displayed a lowering of
mood in response to tryptophan depletion (deﬁned as an increase of
≥10 points on the POMS depression scale) (Benkelfat et al., 1994).AMPT
T0 T0T24 T24T30 T30T48 T48
ross the placebo (ﬁgure to the left) and AMPT sessions (ﬁgure to the right) for all 4 session
stration of AMPT/placebo (blue color), T24 represents the POMS tension scores of 24 h post
post administration of AMPT/placebo (gold color), and T48 represents the POMS tension
e standard error of the mean. The red stars show that the POMS tension scores at T24 and
up (Mann–Whitney test, p b 0.01).
Placebo
T0 T0T24 T24T30 T30T48 T48
AMPT
T0 T0T24 T24T30 T30T48 T48
Fig. 10. Thisﬁgure shows the change in the POMS fatigue scores in both the LR andHRgroups across the placebo (ﬁgure to the left) andAMPT sessions (ﬁgure to the right) for all 4 session
time points. That is, T0, T24, T30, and T48where T0 represents the baseline score prior to administration of AMPT/placebo (blue color), T24 represents the POMS fatigue scores of 24 h post
administration of AMPT/placebo (green color), T30 represents the POMS fatigue scores 30 h of post administration of AMPT/placebo (gold color), and T48 represents the POMS fatigue
scores 48 h of post administration of AMPT/placebo (purple color). The error bars represent the standard error of themean. The red stars show that the POMS fatigue scores at T24 and T30
differed signiﬁcantly between the placebo and AMPT sessions in the HR but not the LR group (Mann–Whitney test, p b 0.01).
350 J. Savitz et al. / NeuroImage: Clinical 2 (2013) 341–355Similarly, 8 out of 16 subjects with a positive family history of bipolar or
unipolar depression showed a tryptophan depletion-associated in-
crease in depressive symptoms (deﬁned by at least 1 point increase
on the POMS depression scale) compared with one out of 11 subjects
without a family history of depression (Klaassen et al., 1999). Healthy
individuals with a family-history of bipolar disorder also showed a
modest decline in mood compared with low-risk healthy controls dur-
ing tryptophan depletion (Quintin et al., 2001). More recently, van der
Veen et al. (2007) reported a greater lowering of mood concomitant
with a stronger amygdala response to fearful faces in healthy individ-
uals with a family history of unipolar depression compared with
healthy controls without a family history of depression during trypto-
phan depletion.
The variable mood response to AMPT in the high-risk group
(Figs. 3–11) suggests that the vulnerability for developing anxiety,
depression, and/or fatigue in response to catecholamine depletion isPlacebo
T0 T0T24 T24T30 T30T48 T48
Fig. 11. Thisﬁgure shows the change in the Stanford Sleepiness Scale (SSS) scores in both the LR
for all 4 session time points. That is, T0, T24, T30, and T48where T0 represents the baseline SSS s
24 h post administration of AMPT/placebo (green color), T30 represents the SSS scores of 30 h p
post administration of AMPT/placebo (purple color). The error bars represent the standard erro
between the placebo and AMPT sessions in the HR but not the LR group (Mann–Whitney test,either absent in some HR subjects (since some subjects may actually
be resilient given that they have remained healthy) or that
dysregulation of the catecholaminergic system is only one of many
pathophysiological mechanisms underpinning the development of
mood disorders.
5. PET imaging
An additional aim of the studywas to examine the neurophysiolog-
ical correlates of catecholamine depletion across the entire sample,
and to test whether HR subjects show differences in cerebral glucose
utilization compared with LR subjects when subjected to catechol-
amine depletion. Our most salient results were as follows.
A signiﬁcant increase was found in regional cerebral glucosemetab-
olism in the ventral striatum, bilaterally, during catecholamine deple-
tion in the combined HR and LR groups (Tables 3 and 5, Figs. 12a, 13).AMPT
T0 T0T24 T24T30 T30T48 T48
andHR groups across theplacebo (ﬁgure to the left) andAMPT sessions (ﬁgure to the right)
core prior to administration of AMPT/placebo (blue color), T24 represents the SSS scores of
ost administration of AMPT/placebo (gold color), and T48 represents the SSS scores of 48 h
r of the mean. The red stars show that the SSS scores at T24 and T30 differed signiﬁcantly
p b 0.01).
Table 3
Results of ROI analysis showing regions of increased metabolic rate in the AMPT versus the placebo condition for all subjects.
ROI Analysis
Increased metabolism in the AMPT versus the placebo condition
ROI Cluster size T score Uncorrected p-value FWE p-value Peak coordinates
X Y Z
Left ventral striatum 173 3.05 0.003 0.054 −12 11 0
Right ventral striatum 246 5.46 b0.001 b0.001 13 9 −4
Left amygdala 24 3.37 0.001 0.012 −22 −4 −10
Right amygdala 33 3.32 0.002 0.013 21 −4 −10
Left hippocampus 215 3.51 0.001 0.033 −27 −23 −6
Right hippocampus 120 3.68 0.001 0.025 30 −18 −6
Coordinates correspond to the stereotaxic array of Talairach and Tournoux (1988) and denote the distance in millimeters from the anterior commissure, with positive x = right of
midline, positive y = anterior to the anterior commissure, and positive z = dorsal to a plane containing both the anterior and the posterior commissures.
The signiﬁcance threshold was set at >10 contiguous voxels at P b 0.05 (FWE-corrected) computed using the small volume correction provided within SPM5 software.
The ROIs were deﬁned by an 8 mm sphere (4 mm in the case of the amygdala) drawn around the following coordinates: Ventral striatum = ±9, 9,−8; amygdala = ±22,−6,−14;
OFC = ± 20, 40,−20; subgenual ACC = 0, 30,−2; mediodorsal thalamus = ±5,−15, 4; hippocampus = ±28,−20,−10, ventromedial PFC = 0, 54,−8.
The ROI coordinates were obtained from atlases of Mai et al. (2004) and Talairach and Tournoux (1988) except for the ventral striatum where we followed the methodology of
Nusslock et al. (2012) and the ventromedial frontal polar cortex where used the peak coordinate that Hasler et al. (2008) reported to correlate positively with severity of depression
in their sample.
Because of a lack of an a priori hypothesis, no reverse contrast was conducted.
351J. Savitz et al. / NeuroImage: Clinical 2 (2013) 341–355This ﬁnding replicates the results of our previous PET-FDG study that
used the same AMPT dose in individuals who had developed MDD
and healthy controls (Hasler et al., 2008). Bremner et al. (2003) studied
medicated subjects with MDD in remission and reported that AMPT-
induced depressive symptoms were associated with decreased activity
in regions such as the OFC, thalamus, and dorsolateral PFC. However,
the ventral striatum was not speciﬁcally assessed by these researchers.
In addition, we report for the ﬁrst time that compared with LR subjects,Y=9
Drug effect (AMPT>p




Fig. 12. This ﬁgure shows selected SPM image sections indicating changes in normalized cerebra
onstrate the existence of separate peak clusters in the striatum, the hippocampi, and the OFC the s
section showing signiﬁcant increases innormalized glucose utilization in the left and right ventral s
axial image showing the signiﬁcant bilateral increases in normalized glucose utilization in both the
in the combinedHRand LR samples. Figure C is a coronal section showing that comparedwith LR su
the left ventral striatum during catecholamine depletion. Figure D is a coronal section showing th
glucosemetabolism in the left OFC during catecholamine depletion. The signiﬁcance threshold is s
analyses. Stereotaxic coordinates provided beneath each section image denote the distance inmm
(for sagittal sections), positive y indicating anterior (for coronal sections), and positive z indicatinHR subjects showed a greater increase in regional cerebral glucose me-
tabolism in the left ventral striatum during catecholamine depletion
(Table 6, Fig. 12c).
Compared with LR subjects, HR subjects showed a greater increase
in regional cerebral glucosemetabolism in the left OFC during catechol-
amine depletion (Table 6, Fig. 12d). Bremner et al. (2003) reported that
AMPT-induced depressive symptoms were associated with decreased




l glucose metabolismmeasured using [18F]ﬂuorodeoxyglucose PET. In order to visually dem-
igniﬁcance thresholds for the ﬁgures were set at p b 0.005 uncorrected. Figure A is a coronal
triata in theAMPTversus placebo condition in the combinedHRand LR samples. Figure B is an
striata (anteriorly) and the hippocampus, (posteriorly), in theAMPT versus placebo condition
bjects, theHR subjects displayed a greater increase in regional cerebral glucosemetabolism in
at compared with LR subjects, HR subjects displayed a greater increase in regional cerebral
et at a voxel level pcorrected b .05 using the FDR test to correct for comparisons in the regional
from the stereotaxic origin (anterior commissure), with positive x indicating right of midline
g dorsal (for horizontal sections).
Table 4
Results of ROI analysis showing regions of signiﬁcantly increased metabolic rate in the HR versus the LR groups in the AMPT condition.
ROI analysis
ROI Cluster size T score Uncorrected P FWE p-value Peak coordinates
Left amygdala 31 2.86 0.007 0.052 −21 −8 −8
Note: No regions showed signiﬁcantly increased metabolism in the HR Versus the LR Group in the placebo condition.
The interpretation of the stereotaxic coordinates and the deﬁnition of the regions-of-interest are as described in the legend for Table 3.
The signiﬁcance threshold was set at >10 contiguous voxels at P b 0.05 (FWE-corrected) computed using the small volume correction provided within SPM5 software.
Because of a lack of an a priori hypothesis, no reverse contrasts were conducted.
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with decreased OFC metabolism in both healthy controls and remitted
patients with MDD as well as reduced OFC metabolism in the healthy
control group versus the MDD group under both placebo and AMPT
(Hasler et al., 2008). The discrepancy in results reported here potential-
ly reﬂects differences in subject group (HR versus remittedMDD) or dif-
ferences in sex ratio. The majority of subjects in the Hasler et al. (2008)
study were female while 9 out of 14 subjects in this study were males.
We found an increase in regional cerebral glucose metabolism in
the amygdala, bilaterally, during catecholamine depletion in the com-
bined HR and LR groups (Table 3). In addition, compared with LR sub-
jects, HR subjects showed a greater increase in regional cerebral
glucose metabolism in the left amygdala during catecholamine deple-
tion (Table 6). The amygdala sends abundant efferent anatomical pro-
jections to the ventral striatum (Price and Drevets, 2010). In addition,
axons from the medial VS (including from the cells that share connec-
tional features with the rodent accumbens shell region) terminate in
the bed nucleus of the stria terminalis, indicating a direct striatal inﬂu-
ence on the extended amygdala.
The neuroimaging literature has consistently reported that patients
with MDD show increased amygdala metabolism, speciﬁcally on the
left side, as well as exaggerated hemodynamic responses to negative
emotional stimuli including words, images and emotionally-valenced
faces (reviewed in Drevets, 2001; Savitz and Drevets, 2009b). Based in
part on these data, we hypothesized that increased amygdala activity
in response to negatively-valenced stimuli is a potential endophenotype
for MDD (Savitz and Drevets, 2009b). The greater increase in cerebral
glucose metabolism in the left amygdala in the HR group versus the LR
group during catecholamine depletion provides support to the hypoth-
esis that abnormalities of amygdala function may predispose to the de-
velopment of mood disorders in genetically-vulnerable populations.
Unfortunately, the size of our sample precludes us from testingwhether
members of the HR group were differentially vulnerable to catechol-
amine depletion on the basis of their genetic makeup. For example,Table 5
Results of ROI analysis showing regions of increased metabolic rate in the AMPT versus
the placebo condition for the HR subjects only.
ROI analysis












Left ventral striatum 64 4.12 0.001 0.045 −14 12 −2
Right ventral striatum 98 4.32 0.001 0.037 15 9 0
Note: No regions showed signiﬁcantly increased metabolism in the AMPT > Placebo
contrast in the LR subjects.
The interpretation of the stereotaxic coordinates and the deﬁnition of the regions-
of-interest are as described in the legend for Table 3.
The signiﬁcance threshold was set at >10 contiguous voxels at P b 0.05 (FWE-corrected)
computed using the small volume correction provided within SPM5 software.
Because of a lack of an a priori hypothesis, no reverse contrasts were conducted.the “short” allele of an insertion/deletion promoter polymorphism
(5- HTTLPR) in the serotonin transporter gene (SLC6A4) has been
previously associated with increased amygdala activity in response
to negatively-valenced faces or decreased amygdala activity in re-
sponse to neutral stimuli (Canli et al., 2005; Hariri et al., 2002).
We found an increase in regional cerebral glucosemetabolism in the
hippocampus, bilaterally, during catecholamine depletion in the com-
binedHRand LR groups (Table 3, Fig. 12b). This result is partially consis-
tent with Hasler et al. (2008) who reported an increase in cerebral
glucose metabolism during catecholamine depletion in the right hippo-
campus/parahippocampal gyrus in a combined group of healthy sub-
jects and remitted MDD subjects. Bremner et al. (2003) reported that
MDD patients who remitted on antidepressant treatment and subse-
quently relapsed after catecholamine depletion displayed increased
glucose metabolism in the hippocampus prior to receiving AMPT. We
thus raise the possibility that the catecholamine depletion-associated
increase in hippocampal activity may be an analog of the changes in
hippocampal activity associated with depression.
In an independent PET study, we found that unmedicated MDD pa-
tients scanned at rest with [15O]-H2O showed increased rCBF in the hip-
pocampus compared with the healthy controls (Savitz et al., 2012).
Further, in an fMRI study we recently reported a greater BOLD response
in currently depressed MDD patients versus LR patients to masked sad
faces in an amygdala-centric neural circuit which included the hippo-
campus (Victor et al., 2012). Moreover, an independent sample of HR
subjects scanned using the samebackwardmaskingparadigmdisplayed
a greater BOLD response to sad versus happy faces than LR subjects in
the parahippocampal gyrus (unpublished data). The increased hippo-
campal activity associated with depression is conceivably consistent
with the morphometric MRI literature which has consistently reported
hippocampal volume reductions in MDD (Savitz and Drevets, 2009a,
2009b). Theoretically, reductions in hippocampal volume in MDD are
reﬂective of a loss of neuropil (Stockmeier et al., 2004) following
glutamate-induced excitotoxicity (McEwen and Magarinos, 1997).Table 6
Results of ROI analysis showing regions of differential metabolism under catecholamine
depletion in HR versus LR subjects (interaction contrast).
ROI analysis
Differential effects of catecholamine depletion in HR versus LR subjects: Metabolism













84 3.23 0.002 0.054 −12 13 −2
Left amygdala 25 2.93 0.004 0.028 −23 −10 −6
Left OFC 133 3.40 0.001 0.041 −22 40 −15
The interpretation of the stereotaxic coordinates and the deﬁnition of the regions-
of-interest are as described in the legend for Table 3.
The signiﬁcance threshold was set at >10 contiguous voxels for which the voxel
p-value corresponded to p(corrected) b 0.05.










Fig. 13.Whole brain voxel-wide analyses showing a signiﬁcant increase in normalized cerebral glucosemetabolism in the ventral striatum, bilaterally, during catecholamine depletion in
the combinedHR and LR groups. Figures A (coronal section) and B (axial section) show the increases in cerebral glucosemetabolism in the left anteroventral putamen and ﬁgures C and D
show the increases in cerebral glucose metabolism in the right anteroventral putamen. The signiﬁcance threshold is set at a voxel level pcorrected b .05 using the FDR test to correct for
comparisons across the whole brain. Stereotaxic coordinates provided beneath each section image denote the distance in mm from the stereotaxic origin (anterior commissure), with
positive x indicating right of midline (for sagittal sections), positive y indicating anterior (for coronal sections), and positive z indicating dorsal (for horizontal sections).
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The small sample size may have led to type I and type II errors and
did not allow for post-hoc analyses examining for example, the effect
of sex on response to AMPT.
We did not examine absolute cerebral glucose metabolism here due
to the input function failures. Nevertheless, we have previously demon-
strated that absolutewhole brainmetabolism is not altered signiﬁcantly
by AMPT (Hasler et al., 2008). In the current sample, we also found no
difference in absolute whole brain glucose metabolism between the
placebo and AMPT conditions (t = 0.42, p = 0.680, 2-tailed test). In
addition, all measurements of regional cerebral glucose metabolism
were normalized by whole brain glucose metabolism.
The inclusion of a group of patientswith remittedMDDor remitted
bipolar disorderwould have allowed us to better contextualize the be-
havioral and neurophysiological response of the HR group to catechol-
amine depletion.Table 7
Results of the voxel-wide analysis showing regions of increased metabolic rate in the
AMPT versus the placebo condition for all subjects.
Whole brain analysis















137 6.76 4.92 b0.001 0.028 0.013 −25 4 −4 L Putamen
328 6.61 4.85 b0.001 0.038 0.013 23 6 −8 R Putamen
6.28 4.70 b0.001 0.068 0.013 25 3 2 R Putamen
6.03 4.58 b0.001 0.105 0.013 15 11 −2 R Putamen
The interpretation of the stereotaxic coordinates is as described in the legend for
Table 3.
The threshold for statistical signiﬁcance was set an FDR-corrected p-value of b0.05.
After correcting for multiple-testing no results remained signiﬁcant in the reverse
contrast.We did not obtain plasma or cerebrospinal ﬂuid (CSF) measure-
ments of monoamine metabolites such as HVA and 3-methoxy-4-
hydroxyphenylglycol (MHPG), and thus could not evaluate whether
the CSF concentrations of these metabolites were associated with cate-
cholamine depletion-induced symptoms of depression and fatigue or
catecholamine depletion-induced changes in glucose metabolism. Pre-
vious studies have reported reductions in plasma levels of MHPG and
HVA in healthy controls (Salomon et al., 1997) and patients with MDD
(Berman et al., 1999; Miller et al., 1996) after administration of AMPT.
The PET D2/3 receptor ligand, 11C-raclopride, which is sensitive to en-
dogenous levels of dopamine could conceivably have been used to pro-
vide more deﬁnitive measures of the degree of intrasynaptic dopamine
depletion induced by AMPT.
The HR group was deﬁned by the presence of relatives with either
BD or MDD and it is theoretically possible that the AMPT response
would differ on the basis of family history of BD versus family history
of MDD. However, family studies have demonstrated that MDD rather
than BD is themost common illness in relatives of individuals with BD,
and twin studies indicate that concordance rates for BD twin pairs are
signiﬁcantly increasedwhen a co-twin of a BD index patient who is di-
agnosed with MDD is classiﬁed as concordant rather than discordant
to the BD index patient: 75% versus 43% (Kieseppa et al., 2004).
A sedation-controlled sham condition (e.g. Berman et al., 1999)
potentially could have allowed the effects of AMPT on fatigue to be
separated from the effects of AMPT on mood. Although it is conceiv-
able that the AMPT-induced sedation may have been interpreted as
low mood by some subjects, this factor cannot account for the differ-
ences in fatigue experienced by the HR and LR groups. Moreover, the
anxiogenic effect of AMPT is arguably difﬁcult to attribute solely to
the effects of sedation.
7. Conclusion
Here we show for the ﬁrst time that healthy individuals who are at




















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































354 J. Savitz et al. / NeuroImage: Clinical 2 (2013) 341–355symptoms of depression, anxiety and fatigue during catecholamine de-
pletion than healthy individualswith no family history of psychiatric ill-
ness. Moreover, this sensitivity to catecholamine depletion in the HR
group was associated with increased cerebral glucose metabolism dur-
ing AMPT in the left ventral striatum, left amygdala, and left OFC. These
results should be treated as preliminary because of the small sample
size. Nevertheless, our data raise the possibility that at least some indi-
viduals with a genetic vulnerability tomood disorders have constitutive
abnormalities in central dopaminergic function that trigger the devel-
opment of affective illness in the presence of other genetic risk factors
or environmental insults.
Supplementary data to this article can be found online at http://
dx.doi.org/10.1016/j.nicl.2013.02.004.
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